FDA Approves Long-Acting HIV Prevention Drug Lenacapavir
TL;DR
The FDA has approved Gilead Sciences' lenacapavir as a twice-yearly PrEP drug to prevent HIV, showing high effectiveness in clinical trials, but concerns remain about its high cost and accessibility.
- FDA Approves ‘Breakthough’ Drug to Prevent HIV Gizmodo
- Yeztugo Lenacapavir Is Now the First and Only FDA Approved HIV Prevention Option Offering 6 Months of Protection Gilead Sciences
- Regulators Approve Lenacapavir for H.I.V. Prevention The New York Times
- FDA approves powerful HIV prevention drug: What to know about Yeztugo NBC News
- Gilead’s CEO on the approval of a powerful new drug to prevent HIV STAT
Want the full story? Read the original reporting
Read on Gizmodo